登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 2025年11月6日，浙江昂利康制药股份有限公司（以下简称"公司"或"本公司"）接到公司实际控制人吕 慧浩先生函告，获悉吕慧浩先生办理了质押式回购部分购回并解除质押业务，现将有关情况公告如下： 注：上表中"已质押股份限售和冻结数量"和"未质押股份限售和冻结数量"中的限售部分为高管锁定股。 三、其他说明 公司实际控制人吕慧浩先生资信状况良好，具备相应的资金偿还能力，所质押的股份不存在平仓风险或 被强制过户风险，不会导致公司的实际控制权发生变更，不会对公司生产经营、治理等产生实质性影 响。 公司将持续关注其质押变动情况及风险，并及时履行信息披露义务。 四、备查文件 1、股份解除质押的证明文件。 一、股东股票质押式回购部分购回并解除质押的基本情况 ■ 二、股东股份质押的基本情况 截至2025年11月5日，上述股东及一致行动人所持质押股份情况如下： ■ 董事会 2025年11月7日 特此公告。 浙江昂利康制药股份有限公司 ...

关于公司实际控制人股票质押式回购部分购回并解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002940 证券简称：昂利康 公告编号：2025-080 浙江昂利康制药股份有限公司 三、其他说明 公司实际控制人吕慧浩先生资信状况良好，具备相应的资金偿还能力，所质押的股份不存在平仓风险或 被强制过户风险，不会导致公司的实际控制权发生变更，不会对公司生产经营、治理等产生实质性影 响。 公司将持续关注其质押变动情况及风险，并及时履行信息披露义务。 四、备查文件 2025年11月6日，浙江昂利康制药股份有限公司（以下简称"公司"或"本公司"）接到公司实际控制人吕 慧浩先生函告，获悉吕慧浩先生办理了质押式回购部分购回并解除质押业务，现将有关情况公告如下： 一、股东股票质押式回购部分购回并解除质押的基本情况 ■ 二、股东股份质押的基本情况 截至2025年11月5日，上述股东及一致行动人所持质押股份情况如下： ■ 注：上表中"已质押股份限售和冻结数量"和"未质押股份限售和冻结数量"中的限售部分为高管锁定 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 浙江昂利康制药股份有限公司（以下简称"公司"或"昂利康"）于 2025 年 11 月 6 日召开经营管理层会议，同意公司调整 2025 年度日常关联交易预计事 项，现将具体情况公告如下： 一、日常关联交易基本情况 （一）2025 年度日常关联交易预计情况 公司于 2025 年 4 月 24 日召开了第四届董事会第七次会议、第四届监事会第 五次会议，于 2025 年 7 月 4 日召开经营管理层会议，同意公司及子公司与关联 方及其子公司 2025 年度日常关联交易预计额度为不超过人民币 1,592 万元（不 含税），具体内容详见公司在《证券时报》及巨潮资讯网（www.cninfo.com.cn） 上刊载的《关于公司 2025 年度日常关联交易预计的公告》（公告编号：2025-024）、 《关于增加 2025 年度日常关联交易预计额度的公告》（公告编号：2025-053）。 现由于公司与关联方浙江白云山昂利康制药股份有限公司（以下简称"白云 山昂利康"）、浙江海禾康生物制药有限公司（以下简称"海禾康"）经营活动需 要 ...

证券代码：002940 证券简称：昂利康 公告编号：2025-080 浙江昂利康制药股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 2025 年 11 月 6 日，浙江昂利康制药股份有限公司（以下简称"公司"或"本 公司"）接到公司实际控制人吕慧浩先生函告，获悉吕慧浩先生办理了质押式回 购部分购回并解除质押业务，现将有关情况公告如下： 二、股东股份质押的基本情况 截至 2025 年 11 月 5 日，上述股东及一致行动人所持质押股份情况如下： | 股东名称 | 持股数量 （股） | 持股比 例 | 累计质押 股份数量 | 占其所 持股份 | 占公 司总 | 已质押股 份限售和 | 已质押股份情况 占 | 已 质 | 未质押股份情况 未质押股 份限售和 | 占未质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | （股） | 比例 | 股本 比例 | 冻结数量 （股） | 押 比例 | 股 份 | 冻结数量 （股） | 押股份 比例 | | 嵊 ...

Group 1 - The core point of the news is that Anglikon experienced a decline of 5.14% in its stock price, reaching 38.73 yuan per share, with a trading volume of 711 million yuan and a turnover rate of 9.47%, resulting in a total market capitalization of 7.813 billion yuan [1] - Anglikon Pharmaceutical Co., Ltd. is located in Shengzhou, Zhejiang Province, and was established on December 30, 2001, with its listing date on October 23, 2018. The company specializes in the research, production, and sales of chemical raw materials and formulations [1] - The main business revenue composition of Anglikon includes formulations at 43.46%, raw materials at 39.82%, specialty intermediates at 12.44%, others at 3.72%, and pharmaceutical excipients at 0.56% [1] Group 2 - From the perspective of major fund holdings, Invesco Great Wall Fund has a significant position in Anglikon, with its Invesco Great Wall Medical Industry Stock A (022081) increasing its holdings by 72,000 shares in the third quarter, totaling 120,000 shares, which accounts for 5.98% of the fund's net value, ranking as the ninth largest holding [2] - The Invesco Great Wall Medical Industry Stock A (022081) was established on January 24, 2025, with a latest scale of 31.4463 million. Since its inception, it has achieved a return of 36.99% [2] - The fund manager, Qiao Haiying, has a tenure of 11 years and 58 days, with the total asset scale of the fund being 1.182 billion yuan. The best fund return during her tenure is 147.43%, while the worst return is -12.35% [2]

Core Viewpoint - The company, Zhejiang Anglikang Pharmaceutical Co., Ltd., has completed its share repurchase program, acquiring a total of 3,599,700 shares, which represents 1.78% of its total share capital, within the stipulated timeframe and budget [3][4][6]. Summary by Sections Share Repurchase Plan - The company approved a share repurchase plan on November 4, 2024, with a budget between RMB 50 million and RMB 70 million, and a maximum repurchase price of RMB 21.07 per share [2]. Implementation Details - The share repurchase was executed through a centralized bidding method, with the first purchase occurring on November 28, 2024, where 688,000 shares were acquired [3]. - By the end of the repurchase period on November 3, 2025, the company had repurchased a total of 3,599,700 shares, with a maximum price of RMB 17.00 per share and a minimum price of RMB 12.17 per share, totaling approximately RMB 50.00 million [4]. Compliance and Impact - The repurchase complied with relevant laws and regulations, ensuring no significant impact on the company's financials, operations, or shareholder interests [6]. - The repurchased shares will be used for employee stock ownership plans or equity incentives, and any unutilized shares within three years will be canceled, reducing the registered capital accordingly [10]. Trading Activity of Related Parties - During the repurchase period, the company's major stakeholders, including directors and supervisors, did not engage in buying or selling the company's shares, except for a planned reduction by a supervisor who sold 159,000 shares [7]. Regulatory Compliance - The company adhered to the regulations regarding the timing and pricing of share repurchases, ensuring no purchases were made during sensitive periods that could affect stock prices [8][9].

Group 1 - The core point of the article is that Anglikon announced the completion of its share repurchase program, which will expire on November 3, 2025 [1] - The company repurchased a total of 3,599,700 shares, representing 1.78% of its total share capital [1]

Group 1 - Company announced a share buyback plan that will expire on November 3, 2025, with a total of approximately 3.6 million shares repurchased, accounting for 1.78% of total share capital [1] - The highest transaction price during the buyback was 17 CNY per share, while the lowest was 12.17 CNY, with a total transaction amount of approximately 50 million CNY [1] - For the first half of 2025, the company's revenue composition is entirely from the pharmaceutical manufacturing industry, with a 100% share [1] Group 2 - The company's market capitalization is currently 8.2 billion CNY [2] - The industry is experiencing a significant increase in overseas orders, with a growth of 246%, covering over 50 countries and regions [2] - Concerns have been raised about potential malicious competition in the industry, as some entities are reportedly selling at a loss [2]

Core Viewpoint - The company, Anglikon (002940.SZ), has completed its share repurchase program, having repurchased a total of 3,599,700 shares, which represents 1.78% of its total share capital [1] Summary by Relevant Sections - **Share Repurchase Details** - The company repurchased shares through a dedicated securities account via centralized bidding [1] - The highest transaction price was 17.00 CNY per share, while the lowest was 12.17 CNY per share [1] - The total amount spent on the repurchase was 50,001,275.28 CNY, excluding transaction fees [1] - **Compliance and Strategy** - The share repurchase complies with relevant laws, regulations, and normative documents [1] - The repurchase aligns with the company's established repurchase plan [1]

证券代码：002940 证券简称：昂利康 公告编号：2025-079 浙江昂利康制药股份有限公司 关于回购公司股份期限届满暨回购实施完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 浙江昂利康制药股份有限公司（以下简称"公司"）于 2024 年 11 月 4 日召 开第四届董事会第六次会议，审议通过了《关于回购公司股份方案的议案》，同 意公司使用自有资金及股票回购专项贷款以集中竞价的方式回购公司部分已发 行的社会公众股份，回购的股份将用于后续员工持股计划或者股权激励。本次回 购股份的资金总额不低于人民币5,000万元（含）且不超过人民币7,000万元（含）， 回购价格不超过人民币 21.07 元/股（含）。具体回购股份的数量以公司实际回购 的股份数量为准。本次回购股份的实施期限为自董事会审议通过本次回购股份方 案之日起不超过 12 个月。具体内容详见公司于 2024 年 11 月 5 日、2024 年 11 月 8 日在指定信息披露媒体《证券时报》及巨潮资讯网（www.cninfo.com.cn）上 刊载的《关于回购公司股份方案暨收到<贷款承诺书>的 ...